Equities Analysts Set Expectations for VTGN Q1 Earnings

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) – Equities researchers at William Blair issued their Q1 2027 earnings estimates for VistaGen Therapeutics in a report released on Wednesday, June 18th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.37) for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for VistaGen Therapeutics’ current full-year earnings is ($1.77) per share. William Blair also issued estimates for VistaGen Therapeutics’ Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.48) EPS and Q4 2027 earnings at ($0.41) EPS.

VistaGen Therapeutics Trading Down 13.4%

NASDAQ VTGN opened at $2.06 on Thursday. The company has a fifty day simple moving average of $2.31 and a two-hundred day simple moving average of $2.57. The stock has a market cap of $60.07 million, a P/E ratio of -1.24 and a beta of 0.70. VistaGen Therapeutics has a 12-month low of $1.90 and a 12-month high of $4.21.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Tuesday, June 17th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.10. The company had revenue of ($0.01) million during the quarter, compared to the consensus estimate of $0.18 million. VistaGen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 58.88%. During the same period last year, the firm earned ($0.25) earnings per share.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC purchased a new position in shares of VistaGen Therapeutics in the first quarter worth $25,000. Two Sigma Advisers LP purchased a new position in shares of VistaGen Therapeutics in the fourth quarter worth $35,000. Man Group plc purchased a new position in shares of VistaGen Therapeutics in the fourth quarter worth $54,000. Bank of America Corp DE raised its holdings in shares of VistaGen Therapeutics by 1,068.0% in the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after buying an additional 19,331 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in shares of VistaGen Therapeutics in the fourth quarter worth $66,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.